Switch theme
Sign up to access all valuation multiples
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
2012
391
LTM Revenue $9.0M
LTM EBITDA -$437M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Avidity Biosciences has a last 12-month revenue (LTM) of $9.0M and a last 12-month EBITDA of -$437M.
In the most recent fiscal year, Avidity Biosciences achieved revenue of $10.9M and an EBITDA of -$376M.
Avidity Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Avidity Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.0M | XXX | $10.9M | XXX | XXX | XXX |
| Gross Profit | $9.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$437M | XXX | -$376M | XXX | XXX | XXX |
| EBITDA Margin | -4856% | XXX | -3452% | XXX | XXX | XXX |
| EBIT | -$445M | XXX | -$379M | XXX | XXX | XXX |
| EBIT Margin | -4952% | XXX | -3477% | XXX | XXX | XXX |
| Net Profit | -$401M | XXX | -$322M | XXX | XXX | XXX |
| Net Margin | -4465% | XXX | -2958% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Avidity Biosciences's stock price is $31.
Avidity Biosciences has current market cap of $3.7B, and EV of $2.4B.
See Avidity Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $3.7B | XXX | XXX | XXX | XXX | $-3.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Avidity Biosciences has market cap of $3.7B and EV of $2.4B.
Avidity Biosciences's trades at 216.6x EV/Revenue multiple, and -6.3x EV/EBITDA.
Equity research analysts estimate Avidity Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avidity Biosciences has a P/E ratio of -9.3x.
See valuation multiples for Avidity Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 262.5x | XXX | 216.6x | XXX | XXX | XXX |
| EV/EBITDA | -5.4x | XXX | -6.3x | XXX | XXX | XXX |
| EV/EBIT | -5.3x | XXX | -6.2x | XXX | XXX | XXX |
| EV/Gross Profit | 262.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.3x | XXX | -11.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAvidity Biosciences's last 12 month revenue growth is 17%
Avidity Biosciences's revenue per employee in the last FY averaged $28K, while opex per employee averaged $1.0M for the same period.
Avidity Biosciences's rule of 40 is -2426% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Avidity Biosciences's rule of X is -4814% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Avidity Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | -4856% | XXX | -3452% | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2426% | XXX | -3435% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4814% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2786% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3577% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avidity Biosciences acquired XXX companies to date.
Last acquisition by Avidity Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Avidity Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Avidity Biosciences founded? | Avidity Biosciences was founded in 2012. |
| Where is Avidity Biosciences headquartered? | Avidity Biosciences is headquartered in United States of America. |
| How many employees does Avidity Biosciences have? | As of today, Avidity Biosciences has 391 employees. |
| Who is the CEO of Avidity Biosciences? | Avidity Biosciences's CEO is Ms. Sarah Boyce. |
| Is Avidity Biosciences publicy listed? | Yes, Avidity Biosciences is a public company listed on NAS. |
| What is the stock symbol of Avidity Biosciences? | Avidity Biosciences trades under RNA ticker. |
| When did Avidity Biosciences go public? | Avidity Biosciences went public in 2020. |
| Who are competitors of Avidity Biosciences? | Similar companies to Avidity Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Avidity Biosciences? | Avidity Biosciences's current market cap is $3.7B |
| What is the current revenue of Avidity Biosciences? | Avidity Biosciences's last 12 months revenue is $9.0M. |
| What is the current revenue growth of Avidity Biosciences? | Avidity Biosciences revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Avidity Biosciences? | Current revenue multiple of Avidity Biosciences is 262.5x. |
| Is Avidity Biosciences profitable? | Yes, Avidity Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Avidity Biosciences? | Avidity Biosciences's last 12 months EBITDA is -$437M. |
| What is Avidity Biosciences's EBITDA margin? | Avidity Biosciences's last 12 months EBITDA margin is -4856%. |
| What is the current EV/EBITDA multiple of Avidity Biosciences? | Current EBITDA multiple of Avidity Biosciences is -5.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
